|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's Range||5.16 - 5.79|
|52 Week Range||0.91 - 5.79|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||3.69|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
IVERIC bio announced that Glenn Sblendorio, CEO and President, will present a Company overview at the Evercore ISI 2nd Annual HealthCONx Conference.
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
If you're interested in IVERIC bio, Inc. (NASDAQ:ISEE), then you might want to consider its beta (a measure of share...
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
On a per-share basis, the New York-based company said it had a loss of 30 cents. The company's shares closed at $1.44. A year ago, they were trading at $2.63. _____ This story was generated by Automated ...